Results Between 2015–2021, 1681 cases were discussed. Table 1 demonstrates VC baseline characteristics. Overall, most cases were New Diagnostic Case (39%), followed by Re-discussion (33%) and New Case Consultation (27%). Re-discussion cases have increased since VC first started. Mean age was 76.2 (SD 11.3) years old, with almost equal males and females (51% and 49%). In total, 333 GPs used the service. The majority of cases being discussed were from outside of Dublin (75%). VC patients were complex, with a mean of 7.1 (SD 3.4) comorbidities, and on a mean of 9.3 (SD 4.0) medications. VC patients had a mean clinical frailty score of 3.8 (SD 1.7) which is significantly (P = 0.006) higher compared to the HFU (2.8 [SD 1.4]). In total, there were 955 (57%) medication adjustments advised, 343 (20%) echocardiograms and 145 (9%) natriuretic peptides (NP) requested as an outcome from the VC. Overall, there were 217 (13%) onward referrals of any sort. This included hospital outpatient (n = 98, 6%), HFU (n = 52, 3%) and HF specialist nurse (n = 16, 1%). Figure 1 demonstrates ‘What the GP would have done if there was no VC service’. Without the VC service, there would have been 93% of onward referrals to the hospital. This would have included outpatient clinics (n =641, 50%), HFU (n = 441, 34%), and acute (n = 92, 7%) or emergency services (n = 18, 1%). Figure 2 demonstrates the incremental use of GP requested NP and echocardiography as a potential marker of improved HF diagnostic knowledge transfer to the community.

Conclusions HFVC is now established, in particular for more frail patients. There has been an increase in re-discussion cases, which demonstrates that VC can be used as a tool for continued care, in addition to a service that reduces onward hospital referrals. We have witnessed evolving practice change in community reflecting improved understanding of community HF care. This platform should be looked at in general cardiology and other chronic disease management settings.

Moderated poster session 2

24 SYSTEMATIC REVIEW OF STRENGTH OF EVIDENCE SUPPORTING THE APPROVAL AND CLINICAL USE OF HIGH-RISK MEDICAL DEVICES IN CARDIOVASCULAR MEDICINE: AN UPDATE FROM THE CORE-MD CONSORTIUM

L McGovern, G Siotis, A Freerk, T Melvin, G McGauran, R Geertsma, P Schnelli-Indest, AG Fraser, W Deender, R Byrne. Cardiovascular Research Institute (CVRI) Dublin, Mater Private Network, RCSI, Dublin, Ireland; University Hospital (BUH), Bern, Switzerland; Health Products Regulatory Authority (HPRA), Dublin, Ireland; Institute for Public Health and the Environment, Utrecht, Netherlands; Tirol, Austria; University Hospital of Wales, Cardiff, UK; European Society of Cardiology (ESC)

Introduction Implementation of the new Medical Device Regulation (MDR) 2017/745 by the European Union (EU) challenges the medical community to engage with regulators, notified bodies and industry to develop transparent, rigorous and proportionate methods to evaluate the clinical safety and efficacy of medical devices and monitor their performance. Against this background, as part of the EU Horizon 2020 funded project – CORE-MD – we performed a systematic review of clinical evidence available for selected class III implantable devices used in cardiovascular medicine.

Methods A systematic literature review was conducted using Ovid, MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) of studies of prospective design evaluating pre specified high-risk medical devices in the field of cardiovascular medicine between January 2000 and August 2021. We included selected high-risk devices that received CE Mark approval from the year 2000 onwards. The date of CE-Mark approval was defined through press releases available online, information provided by regulatory sources such as notified bodies, and personal communications with the corresponding manufacturers. We focused on any study of prospective design (non-randomised or randomised clinical trials of any design) in humans. We excluded retrospective studies, case reports, reviews, systematic reviews, meta-analyses, and expert opinion documents. We performed title and abstract screening, full-text review, risk of bias evaluation and data collection independently and in duplicate.

Results The following classes of high-risk medical devices in the cardiovascular field were evaluated: left atrial appendage occlusion (LAOO), transcatheter aortic valve implantation (TAVI); transcatheter mitral valve repair/replacement (TMVR); leadless pacemakers; subcutaneous implantable cardioverter-defibrillators (S-ICD), bioresorbable scaffolds for percutaneous coronary intervention; and surgical heart valve replacement for native aortic and mitral valve pathologies. For the latter group, a total of 17 surgical aortic valves and 4 surgical mitral valves were included. An interim report of the systematic review of the CORE-MD consortium with a focus on surgical heart valve replacement will be available for presentation at ICS 2022. To date, the literature search has identified 3696 and 4901 potentially eligible papers in the surgical mitral valves category and surgical aortic valves categories, respectively.

Conclusion The goal of the CORE-MD consortium is to develop awareness of and expertise within the clinical community in Europe in relation to the regulation of high-risk medical devices. Data from the systematic review of high-risk cardiovascular devices will enable comparison of strength of evidence within and across classes of devices in cardiovascular medicine and facilitate comparison against high-risk devices in other medical specialties including orthopaedics and diabetes.

25 A SNAPSHOT OF CARDIOVASCULAR HEALTH IN BONE MARROW TRANSPLANT RECIPIENTS IN IRELAND

R Evans, C Armstrong, E Vandenberghhe, R Murphy. Department of Cardiology, St. James’s Hospital, Dublin, Ireland; Department of Haematology, St. James’s Hospital, Dublin, Ireland

Introduction Bone Marrow Transplantation has been completed in Ireland in a single site, St James’s Hospital, since 1984. The European Society for Blood and Marrow Transplantation (EBMT), Transplantation Complication Working Party (TCWP) published recommendations in 2016 on screening and preventative practices on cardiovascular disease in post-Bone Marrow Transplant (BMT) patients, as there is evidence of both earlier onset and overall increased risk of cardiovascular disease in this patient cohort. There is a paucity of evidence identifying the prevalent risk factors amongst the Irish cohort of BMT recipients, and the affect these risks have on their cardiovascular outcomes.